Track topics on Twitter Track topics that are important to you
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...
MONDAY, Oct. 3, 2016 -- The blood thinner Xarelto may pose a slightly greater risk of serious bleeding than Pradaxa in patients with the abnormal heartbeat known as atrial fibrillation, new research s...
* Believes statements published in 'Handelsblatt' on Nov. 9. about Xarelto are misleading
NewsPharmaceutical company Boehringer Ingelheim Pharmaceuticals Inc., presented two studies at the American Society of Hematology Annual Meeting in San Diego, which showed patients who were newly diag...
Janssen and Bayer have stopped a phase 3 trial of Xarelto early after results showed it can cut deaths, heart attacks and strokes compared to aspirin. The promising data paves the way for a lucrativ...
NewsPhase 3b study shows significantly less bleeding with Xarelto (rivaroxaban) compared to Warfarin in people with non-valvular atrial fibrillation following percutaneous coronary intervention with s...
The Phase III trial COMPASS evaluating the efficacy and safety of Xarelto (rivaroxaban) for the prevention…
The U.S. Food and Drug Administration on Tuesday said it has determined the widely-used blood thinner Xarelto to be safe and effective for patients with the heart condition atrial fibrillation after s...
Oct 11 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it has determined the widely-used blood thinner Xarelto to be safe and effective for patients with the heart condition atrial f...
Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short- and long-term anticoagulation, mainly due to their ease of use and the lack of monitoring requirements. With gro...